Updates are available Correction dated 2025-02-21
Click to view Correction: https://doi.org/10.1038/s41467-025-57187-w
-
Authors
Contreras-Sanz, A. https://orcid.org/0009-0004-9315-6238
Negri, G. L. https://orcid.org/0000-0001-7722-8888
Reike, M. J.
Oo, H. Z. https://orcid.org/0009-0009-8514-2713
Scurll, J. M.
Spencer, S. E. https://orcid.org/0000-0001-6446-1584
Nielsen, K.
Ikeda, K.
Wang, G. https://orcid.org/0000-0002-0225-4173
Jackson, C. L. https://orcid.org/0000-0002-6784-5978
Gupta, S. https://orcid.org/0000-0002-8775-503X
Roberts, M. E. https://orcid.org/0000-0002-5850-7985
Berman, D. M. https://orcid.org/0000-0001-5985-3698
Seiler, R.
Morin, G. B. https://orcid.org/0000-0001-8949-4374
Black, P. C. https://orcid.org/0000-0002-2919-7068
- License Information
-
More Information
Article History
Received: 15 April 2024
Accepted: 18 December 2024
First Online: 1 February 2025
Change Date: 21 February 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-025-57187-w
Competing interests
: A.C.-S. has consulted for Sustained Therapeutics. D.M.B. serves on the Scientific Advisory Board and has equity in Acrivon Therapeutics. Peter Black has consulted for AbbVie, Astellas Pharma, AstraZeneca, EMD-Serono, Ferring, Pfizer, Janssen Oncology, Bayer, Merck, Sanofi Canada, Bristol-Myers Squibb, Prokarium, Combat, Nonagen, Nanobot, NanOlogy, Photocure, Sumitomo, TerSera, Tolmar, and Verity. He shares a patent with Veracyte which played no role or is linked to the work presented here (Inventors Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Peter Black; EP 3 571 322 B8 date of publication and mention of the grant patent 07.06.2023). R.S. has consulted for Janssen Oncology. He shares a patent with Veracyte which played no role or is linked to the work presented here (Inventors Elai Davicioni, Hussam Al-Deen Ashab, Nicholas Erho, Peter Black; EP 3 571 322 B8 date of publication and mention of the grant patent 07.06.2023). The rest of authors had no conflict of interest.
